By Fineline Cube 
Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its YL242, a VEGF-targeted antibody drug conjugate (ADC). This marks a significant milestone in the clinical development of YL242.
Development and Technology
YL242 was developed through Medilink’s proprietary TMALIN technology platform. The drug is currently under IND review in China, highlighting the company’s commitment to advancing innovative therapies for patients.-Fineline Info & Tech